Review



human ccl14 elisa kit  (Boster Bio)


Bioz Verified Symbol Boster Bio is a verified supplier
Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Boster Bio human ccl14 elisa kit
    Human Ccl14 Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccl14+elisa+kit/Human+CCL14+ELISA+Kit+EZ-Set/pm41559739-94-12-16
    Average 94 stars, based on 1 article reviews
    human ccl14 elisa kit - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    Clinical Proteomics:

    Article Title: CCL14, identified by multi-omics approach, serves as a novel indicator of disease severity and progression in lymphangioleiomyomatosis
    Article Snippet: Serum concentrations of VEGF-D in samples from 53 disease subjects and 25 healthy controls were quantified using a human VEGF-D ELISA kit (R&D Systems, USA). .. Plasma concentrations of CCL14 in the same cohort were measured using a human CCL14 ELISA kit (Boster Biological Technology, China). ..

    Article Title: CCL14, identified by multi-omics approach, serves as a novel indicator of disease severity and progression in lymphangioleiomyomatosis.
    Article Snippet: Serum concentrations of VEGF-D in samples from 53 disease subjects and 25 healthy controls were quantified using a human VEGF-D ELISA kit (R&D Systems, USA). .. Plasma concentrations of CCL14 in the same cohort were measured using a human CCL14 ELISA kit (Boster Biological Technology, China). ..

    Enzyme-linked Immunosorbent Assay:

    Article Title: CCL14, identified by multi-omics approach, serves as a novel indicator of disease severity and progression in lymphangioleiomyomatosis
    Article Snippet: Serum concentrations of VEGF-D in samples from 53 disease subjects and 25 healthy controls were quantified using a human VEGF-D ELISA kit (R&D Systems, USA). .. Plasma concentrations of CCL14 in the same cohort were measured using a human CCL14 ELISA kit (Boster Biological Technology, China). ..

    Article Title: CCL14, identified by multi-omics approach, serves as a novel indicator of disease severity and progression in lymphangioleiomyomatosis.
    Article Snippet: Serum concentrations of VEGF-D in samples from 53 disease subjects and 25 healthy controls were quantified using a human VEGF-D ELISA kit (R&D Systems, USA). .. Plasma concentrations of CCL14 in the same cohort were measured using a human CCL14 ELISA kit (Boster Biological Technology, China). ..



    Similar Products

    human ccl14 elisa kit  (Boster Bio)
    94
    Boster Bio human ccl14 elisa kit
    Human Ccl14 Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccl14+elisa+kit/Human+CCL14+ELISA+Kit+EZ-Set/pm41559739-94-12-16
    Average 94 stars, based on 1 article reviews
    human ccl14 elisa kit - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    ccl14  (Danaher Inc)
    99
    Danaher Inc ccl14
    Urinary biomarkers levels on day 0 stratified by renal recovery. Day 0 means the day of AKI diagnosis . TIMP-2 tissue inhibitor of metalloproteinases-2, IGFBP-7 insulin-like growth factor-binding protein 7, <t>CCL14</t> C–C motif chemokine ligand 14, NGAL neutrophil gelatinase-associated lipocalin
    Ccl14, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccl14+elisa+kit/Human+MER+ELISA+Kit/pmc10026399-96-2-13
    Average 99 stars, based on 1 article reviews
    ccl14 - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    immunosorbent assay elisa kit  (Boster Bio)
    90
    Boster Bio immunosorbent assay elisa kit
    AXL/SOX2/DKK-1 axis in HUVECs promotes HCC metastasis. (A) DKK-1 and <t>CCL14</t> secretion was significantly downregulated in CM from HUVEC-AXL-KD compared with that from HUVEC-AXL-NC, as detected with a human cytokine antibody array. (B) DKK-1 and CCL14 expression was markedly upregulated in the CM of HUVECs overexpressing AXL (CCL14: p < 0.001; DKK-1: p = 0.003) compared with the CM of HUVEC-AXL-NC, as detected by <t>ELISA</t> assay. (C) AXL siRNA downregulated DKK-1 and CCL14 secretion in the CM of HUVEC-AXL-NC and HUVEC-AXL-OE cells (CCL14: p < 0.001 and p < 0.001; DKK-1: p < 0.001 and p < 0.001). (D) DKK1 siRNA (MHCC-97L: p < 0.001 and p < 0.001; HCC-LM3: p <0.001 and p < 0.001), but not CCL14 siRNA (MHCC-97L: p = 0.126 and p = 0.711; HCC-LM3: p = 0.901 and p = 0.694) could attenuate the effect of the CM from HUVEC-AXL-NC and HUVEC-AXL-OE cells on the migration of HCC-LM3 cells and MHCC-97L cells. (E) SOX2 mRNA expression was significantly increased in HUVEC-AXL-OE cells and decreased in HUVEC-AXL-KD cells compared with HUVEC-AXL-NC cells (HUVEC-AXL-KD: p < 0.001, HUVEC-AXL-OE: p < 0.001). (F) AXL overexpression could significantly increase SOX2 and DKK-1 protein expression in HUVEC-AXL-OE cells compared with HUVEC-AXL-NC cells, and SOX2 siRNA inhibited SOX2 and DKK-1 protein expression in HUVEC-AXL-OE and HUVEC-AXL-NC cells.
    Immunosorbent Assay Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ccl14+elisa+kit/Human+CCL14%2FHCC-1+ELISA+Kit+PicoKine/pmc08191462-105-16-22
    Average 90 stars, based on 1 article reviews
    immunosorbent assay elisa kit - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Urinary biomarkers levels on day 0 stratified by renal recovery. Day 0 means the day of AKI diagnosis . TIMP-2 tissue inhibitor of metalloproteinases-2, IGFBP-7 insulin-like growth factor-binding protein 7, CCL14 C–C motif chemokine ligand 14, NGAL neutrophil gelatinase-associated lipocalin

    Journal: Journal of Intensive Care

    Article Title: Analysis of urinary C–C motif chemokine ligand 14 (CCL14) and first-generation urinary biomarkers for predicting renal recovery from acute kidney injury: a prospective exploratory study

    doi: 10.1186/s40560-023-00659-2

    Figure Lengend Snippet: Urinary biomarkers levels on day 0 stratified by renal recovery. Day 0 means the day of AKI diagnosis . TIMP-2 tissue inhibitor of metalloproteinases-2, IGFBP-7 insulin-like growth factor-binding protein 7, CCL14 C–C motif chemokine ligand 14, NGAL neutrophil gelatinase-associated lipocalin

    Article Snippet: NGAL and CCL14 were measured by enzyme-linked immunosorbent assay (ab119600 (NGAL); ab272201 (CCL14), Abcam, UK).

    Techniques: Biomarker Discovery, Binding Assay

    Predictive accuracy of urinary biomarkers on day 0 for renal non-recovery

    Journal: Journal of Intensive Care

    Article Title: Analysis of urinary C–C motif chemokine ligand 14 (CCL14) and first-generation urinary biomarkers for predicting renal recovery from acute kidney injury: a prospective exploratory study

    doi: 10.1186/s40560-023-00659-2

    Figure Lengend Snippet: Predictive accuracy of urinary biomarkers on day 0 for renal non-recovery

    Article Snippet: NGAL and CCL14 were measured by enzyme-linked immunosorbent assay (ab119600 (NGAL); ab272201 (CCL14), Abcam, UK).

    Techniques:

    ROC curves of clinical model and corresponding urinary biomarkers model on day 0 for predicting renal non-recovery. Day 0 means the day of AKI diagnosis. a Compared with clinical model. Clinical model included non-renal SOFA score and AKI stage. AUC area under the receiver operating characteristics curve, CCL14 C–C motif chemokine ligand 14, TIMP-2 tissue inhibitor of metalloproteinases-2, IGFBP-7 insulin-like growth factor-binding protein 7

    Journal: Journal of Intensive Care

    Article Title: Analysis of urinary C–C motif chemokine ligand 14 (CCL14) and first-generation urinary biomarkers for predicting renal recovery from acute kidney injury: a prospective exploratory study

    doi: 10.1186/s40560-023-00659-2

    Figure Lengend Snippet: ROC curves of clinical model and corresponding urinary biomarkers model on day 0 for predicting renal non-recovery. Day 0 means the day of AKI diagnosis. a Compared with clinical model. Clinical model included non-renal SOFA score and AKI stage. AUC area under the receiver operating characteristics curve, CCL14 C–C motif chemokine ligand 14, TIMP-2 tissue inhibitor of metalloproteinases-2, IGFBP-7 insulin-like growth factor-binding protein 7

    Article Snippet: NGAL and CCL14 were measured by enzyme-linked immunosorbent assay (ab119600 (NGAL); ab272201 (CCL14), Abcam, UK).

    Techniques: Biomarker Discovery, Binding Assay

    NRI and IDI for assessing the contributions of different biomarkers for non-recovery prediction when combing with clinical model

    Journal: Journal of Intensive Care

    Article Title: Analysis of urinary C–C motif chemokine ligand 14 (CCL14) and first-generation urinary biomarkers for predicting renal recovery from acute kidney injury: a prospective exploratory study

    doi: 10.1186/s40560-023-00659-2

    Figure Lengend Snippet: NRI and IDI for assessing the contributions of different biomarkers for non-recovery prediction when combing with clinical model

    Article Snippet: NGAL and CCL14 were measured by enzyme-linked immunosorbent assay (ab119600 (NGAL); ab272201 (CCL14), Abcam, UK).

    Techniques:

    AXL/SOX2/DKK-1 axis in HUVECs promotes HCC metastasis. (A) DKK-1 and CCL14 secretion was significantly downregulated in CM from HUVEC-AXL-KD compared with that from HUVEC-AXL-NC, as detected with a human cytokine antibody array. (B) DKK-1 and CCL14 expression was markedly upregulated in the CM of HUVECs overexpressing AXL (CCL14: p < 0.001; DKK-1: p = 0.003) compared with the CM of HUVEC-AXL-NC, as detected by ELISA assay. (C) AXL siRNA downregulated DKK-1 and CCL14 secretion in the CM of HUVEC-AXL-NC and HUVEC-AXL-OE cells (CCL14: p < 0.001 and p < 0.001; DKK-1: p < 0.001 and p < 0.001). (D) DKK1 siRNA (MHCC-97L: p < 0.001 and p < 0.001; HCC-LM3: p <0.001 and p < 0.001), but not CCL14 siRNA (MHCC-97L: p = 0.126 and p = 0.711; HCC-LM3: p = 0.901 and p = 0.694) could attenuate the effect of the CM from HUVEC-AXL-NC and HUVEC-AXL-OE cells on the migration of HCC-LM3 cells and MHCC-97L cells. (E) SOX2 mRNA expression was significantly increased in HUVEC-AXL-OE cells and decreased in HUVEC-AXL-KD cells compared with HUVEC-AXL-NC cells (HUVEC-AXL-KD: p < 0.001, HUVEC-AXL-OE: p < 0.001). (F) AXL overexpression could significantly increase SOX2 and DKK-1 protein expression in HUVEC-AXL-OE cells compared with HUVEC-AXL-NC cells, and SOX2 siRNA inhibited SOX2 and DKK-1 protein expression in HUVEC-AXL-OE and HUVEC-AXL-NC cells.

    Journal: Frontiers in Oncology

    Article Title: AXL Overexpression in Tumor-Derived Endothelial Cells Promotes Vessel Metastasis in Patients With Hepatocellular Carcinoma

    doi: 10.3389/fonc.2021.650963

    Figure Lengend Snippet: AXL/SOX2/DKK-1 axis in HUVECs promotes HCC metastasis. (A) DKK-1 and CCL14 secretion was significantly downregulated in CM from HUVEC-AXL-KD compared with that from HUVEC-AXL-NC, as detected with a human cytokine antibody array. (B) DKK-1 and CCL14 expression was markedly upregulated in the CM of HUVECs overexpressing AXL (CCL14: p < 0.001; DKK-1: p = 0.003) compared with the CM of HUVEC-AXL-NC, as detected by ELISA assay. (C) AXL siRNA downregulated DKK-1 and CCL14 secretion in the CM of HUVEC-AXL-NC and HUVEC-AXL-OE cells (CCL14: p < 0.001 and p < 0.001; DKK-1: p < 0.001 and p < 0.001). (D) DKK1 siRNA (MHCC-97L: p < 0.001 and p < 0.001; HCC-LM3: p <0.001 and p < 0.001), but not CCL14 siRNA (MHCC-97L: p = 0.126 and p = 0.711; HCC-LM3: p = 0.901 and p = 0.694) could attenuate the effect of the CM from HUVEC-AXL-NC and HUVEC-AXL-OE cells on the migration of HCC-LM3 cells and MHCC-97L cells. (E) SOX2 mRNA expression was significantly increased in HUVEC-AXL-OE cells and decreased in HUVEC-AXL-KD cells compared with HUVEC-AXL-NC cells (HUVEC-AXL-KD: p < 0.001, HUVEC-AXL-OE: p < 0.001). (F) AXL overexpression could significantly increase SOX2 and DKK-1 protein expression in HUVEC-AXL-OE cells compared with HUVEC-AXL-NC cells, and SOX2 siRNA inhibited SOX2 and DKK-1 protein expression in HUVEC-AXL-OE and HUVEC-AXL-NC cells.

    Article Snippet: The protein concentrations of CCL14 and DKK-1 in the supernatants were also measured using an enzyme-linked immunosorbent assay (ELISA) kit (CCL14: EK1123 Boster, Wuhan, China; DKK-1: EK0867 Boster, Wuhan, China) according to the manufacturer’s instructions.

    Techniques: Ab Array, Expressing, Enzyme-linked Immunosorbent Assay, Migration, Over Expression